Approval · Notice of Compliance 17859 · 2016

BRIVLERA: Notice of Compliance 17859

Issued March 9, 2016

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 17859
Date: March 9, 2016
Company: Ucb Canada IncOakville, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)

Products in this notice

Brand	DIN	Status today
BRIVLERA	02452936	Marketed
BRIVLERA	02452944	Marketed
BRIVLERA	02452952	Marketed
BRIVLERA	02452960	Marketed
BRIVLERA	02452979	Marketed
BRIVLERA	02452987	Marketed
BRIVLERA	02452995	Marketed

Medicinal ingredients

BRIVARACETAM 10 MG per TAB
BRIVARACETAM 25 MG per TAB
BRIVARACETAM 50 MG per TAB
BRIVARACETAM 75 MG per TAB
BRIVARACETAM 100 MG per TAB
BRIVARACETAM 10 MG per ML